Global HIV Drugs Market Outlook 2019-2024 – Dominated by Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “HIV
Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s
offering.

Over the years, the rising prevalence of HIV disease worldwide has
positively influenced the demand for HIV drugs. HIV drugs help in
preventing the multiplication of HIV virus, thereby reducing the risk of
its transmission.

According to the report, the global HIV drugs market exceeded a value of
US$ 24.7 Billion in 2018. Looking forward, the market value is projected
to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during
2019-2024.

This report provides a deep insight into the global HIV drugs market
covering all its essential aspects. This ranges from macro overview of
the market to micro details of the industry performance, recent trends,
key market drivers and challenges, SWOT analysis, Porter’s five forces
analysis, value chain analysis, etc.

One of the primary factors catalysing the growth of the global HIV drugs
market is increase in the prevalence of HIV and its diagnosis. Apart
from this, the market is also influenced by a rise in the number of
government initiatives for spreading the awareness amongst people
regarding causes, symptoms and treatments. Moreover, the introduction of
generic drugs, which are cost-effective and chemically identical to
branded drugs, act as another factor that is contributing towards the
demand for HIV drugs.

Market Summary

Based on class, the market has been segmented into multi-class
combination products, nucleoside reverse transcriptase inhibitors,
non-nucleoside reverse transcriptase inhibitors, protease inhibitors,
fusion inhibitors, entry inhibitors – CCR5 co-receptor antagonist and
HIV integrase strand transfer inhibitors.

On the basis of distribution channel, the market is segregated as
hospital pharmacies, retail pharmacies, online pharmacies and others.
Hospital pharmacies currently account for the largest share.

Region-wise, the market has been segmented into Europe, Asia Pacific,
North America, Middle East and Africa, and Latin America. Amongst these,
North America is the leading market accounting for the majority of the
global market.

The competitive landscape of the market has also been examined with some
of the key players being Bristol-Myers Squibb, Gilead Sciences,
GlaxoSmithKline, Johnson & Johnson and Merck.

Key Questions Answered

• How has the global HIV drugs market performed so far and how will it
  perform in the coming years?
• What are the key regions in the global HIV drugs market?
• Which are the popular class types in the global HIV drugs market?
• What are the major distribution channels in the global HIV drugs
  market?
• What are the various stages in the value chain of the global HIV drugs
  market?
• What are the key driving factors and challenges in the global HIV
  drugs market?
• What is the structure of the global HIV drugs market and who are the
  key players?
• What is the degree of competition in the global HIV drugs market?
• How are HIV drugs manufactured?

Topics Covered

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.4 Market Estimation

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global HIV Drugs Market

5.1 Market Overview

5.2 Market Performance

5.3 Price Analysis

5.4 Market Breakup by Drug Class

5.5 Market Breakup by Distribution Channel

5.6 Market Breakup by Region

5.7 Market Forecast

5.8 SWOT Analysis

5.9 Value Chain Analysis

5.10 Porters Five Forces Analysis

6 Market Breakup by Drug Class

6.1 Nucleoside Reverse Transcriptase Inhibitors

6.2 Multi-Class Combination Products

6.3 Protease Inhibitors

6.4 HIV Integrase Strand Transfer Inhibitors

6.5 Non-Nucleoside Reverse Transcriptase Inhibitors

6.6 Entry Inhibitors – CCR5 Co-Receptor Antagonist

6.7 Fusion Inhibitors and Others

7 Market Breakup by Distribution Channel

7.1 Hospital Pharmacies

7.2 Retail Pharmacies

7.3 Online Pharmacies

7.4 Others

8 Market Breakup by Region

8.1 North America

8.2 Europe

8.3 Asia Pacific

8.4 Middle East and Africa

8.5 Latin America

9 HIV Drugs Manufacturing Process

9.1 Product Overview

9.2 Raw Material Requirements

9.3 Manufacturing Process

9.4 Key Success and Risk Factors

10 Competitive Landscape

10.1 Market Structure

10.2 Market Breakup by Key Players

10.3 Profiles of Key Players

10.3.1 Boehringer Ingelheim International GmbH

10.3.2 Merck & Co. Inc.

10.3.3 ViiV Healthcare

10.3.4 AbbVie

10.3.5 F. Hoffmann-La Roche Ltd.

10.3.6 Teva Pharmaceutical Industries Ltd.

10.3.7 Bristol-Myers Squibb

10.3.8 Gilead Sciences Inc.

10.3.9 Johnson & Johnson

10.3.10 Cipla Limited

10.3.11 Daiichi Sankyo

10.3.12 Emcure

10.3.13 Hetero Drugs

10.3.14 Mylan

For more information about this report visit https://www.researchandmarkets.com/r/izpkqn

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Infectious
Diseases Drugs, HIV/AIDS
Drugs